Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Noom and Found represent two distinct weight loss program models gaining popularity among telehealth users. Noom focuses on behavioral psychology and cognitive restructuring, while Found centers on medication-assisted approaches using GLP-1 drugs like semaglutide and tirzepatide. Both platforms serve millions of users, yet clinical outcomes and patient suitability differ significantly between the two.

When evaluating Noom versus Found, it's important to understand what clinical evidence shows about behavioral interventions versus pharmacologic support. Many patients benefit from one approach or the other—or a combination. PlexusDx takes a precision-wellness perspective, offering compounded GLP-1 options and genetic testing to support more individualized treatment planning with qualified healthcare providers.

How Noom and Found Differ in Program Design

Noom operates as a mobile-first coaching platform emphasizing daily weigh-ins, food logging, and cognitive behavioral therapy (CBT) techniques. The app assigns users a color-coded food system and connects them with human coaches. Noom does not prescribe medications but encourages habit change through psychological principles. Founded in 2008, Noom has grown to serve millions globally.

Found, established more recently, takes a medication-centric telehealth model. Providers at Found evaluate patients for GLP-1 eligibility, prescribe medications like semaglutide or tirzepatide, and offer ongoing monitoring via telemedicine. Found also includes behavioral coaching, but the primary intervention is pharmacologic management. This differs fundamentally from Noom's behavioral-first philosophy.

Clinical Evidence: Behavioral Weight Loss vs. GLP-1 Medications

Research on behavioral interventions shows consistent modest benefits. A 2016 meta-analysis in JAMA found behavioral programs yielded average weight loss of 5–8% of baseline body weight over 12 months. CBT-based approaches improve long-term adherence compared to unsupported dieting. Noom's model aligns with this evidence base and may work well for patients seeking structured habit support.

GLP-1 receptor agonists produce substantially larger weight losses in clinical trials. The STEP 4 trial (semaglutide) reported mean weight loss of 17.4% at 68 weeks in people with obesity. SURMOUNT-1 (tirzepatide) showed 21.4% weight loss at 72 weeks. These medications address appetite regulation at a physiologic level, offering more aggressive weight reduction for eligible candidates.

Intervention Type Mean Weight Loss % Duration Primary Mechanism
Behavioral (Noom-style) 5–8% 12 months Habit change, CBT, adherence
GLP-1 Monotherapy (Found-style) 15–21% 12–18 months Appetite suppression, satiety
Combined (Behavioral + GLP-1) 20–28% (estimated) 12+ months Dual pathway: psychology + physiology
Precision GLP-1 (Genetic-informed) 15–25% Ongoing Personalized dosing & monitoring

Cost, Access, and Insurance Coverage Comparison

Noom's subscription costs $60–$200 monthly depending on coaching tier and duration. Most insurance plans do not cover Noom, as it is a consumer wellness app rather than a clinical service. Accessibility is high due to low cost and app-based delivery. Founded on a direct-to-consumer model, Noom has minimal insurance navigation.

Found's model involves telehealth provider visits, lab work, and medication costs. GLP-1 prescription drugs from branded manufacturers (Ozempic, Wegovy, Zepbound, Mounjaro) cost $900–$1,300 monthly without insurance. Some insurance plans now cover GLP-1 for weight management if BMI and comorbidities meet criteria. Found handles insurance verification but out-of-pocket costs remain high for many patients. Compounded alternatives may offer reduced-cost access with qualified provider oversight.

Who Benefits Most: Patient Selection and Clinical Context

Noom works best for patients motivated by behavior change, those with mild-to-moderate weight loss goals, and individuals preferring non-pharmaceutical approaches. People with eating disorders, binge-eating disorder (BED), or low intrinsic motivation may find behavioral-only programs less effective. Noom suits those seeking preventive health coaching and habit reversal.

Found is appropriate for patients with obesity (BMI ≥30) or overweight with comorbidities (diabetes, hypertension), those meeting GLP-1 clinical criteria, and individuals who have not responded adequately to behavioral interventions alone. Contraindications include personal or family history of medullary thyroid cancer, Multiple Endocrine Neoplasia type 2, and pregnancy. Medication-assisted approaches show faster clinical outcomes in this population.

Genetic and Personalization Factors in GLP-1 Response

Emerging research suggests genetic variants in GLP-1 receptor pathways may influence individual medication response and tolerability. Variants in GLP1R, GIPR, FTO, and MC4R genes have been associated with differential weight-loss outcomes in some studies. However, genetic prediction of GLP-1 efficacy is not yet standardized in clinical practice and should not replace medical evaluation.

Precision Peptide Genetic Testing can help identify individual predispositions in peptide-pathway genes, potentially supporting more informed provider conversations about GLP-1 candidacy and dosing expectations. This test reveals genetic markers in genes like GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313). Genetic context may help providers tailor treatment selection and monitoring, though results must be interpreted by a qualified healthcare provider and do not guarantee medication success.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that Noom and Found each address real clinical needs, but neither platform integrates genetic insight into treatment planning. Compounded GLP-1 medications from licensed 503A pharmacies can offer cost-effective alternatives to branded drugs while maintaining clinical oversight. Combining genetic testing with personalized medication protocols may provide more targeted support than behavioral-only or standard-dose medication approaches.

The Precision Peptide Genetic Test ($99 as an add-on or $298 standalone) may help provide context about individual peptide-pathway predispositions. This test examines key genetic variants and can support a more personalized conversation between patients and providers about which treatment modality—behavioral, pharmacologic, or combined—aligns best with individual biology and lifestyle readiness.

Patients considering weight-loss support should work with a qualified healthcare provider to evaluate whether Noom's behavioral focus, Found's GLP-1 model, or a precision-informed compounded GLP-1 program best matches their clinical needs, comorbidities, and treatment goals. PlexusDx compounded semaglutide and tirzepatide options provide an alternative entry point for GLP-1 therapy with personalized provider guidance.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How does Noom differ from Found in terms of weight loss outcomes?

Noom uses behavioral coaching and typically achieves 5–8% weight loss over 12 months. Found prescribes GLP-1 medications with average weight losses of 15–21%. Outcomes depend on patient adherence, baseline BMI, and individual biology—neither is universally superior for all patients.

Is Noom or Found covered by insurance?

Noom is rarely covered as it is a consumer app. Found's GLP-1 medications may be covered by insurance if clinical criteria (BMI, comorbidities) are met, though many plans still require prior authorization. Compounded alternatives may offer lower out-of-pocket costs with provider oversight.

Can genetic testing help predict whether I'll respond to GLP-1?

Precision Peptide Genetic Testing examines genes like GLP1R and GIPR to reveal predispositions in peptide pathways. This may provide context for provider conversations about GLP-1 candidacy, but does not guarantee medication response and should be interpreted with qualified healthcare guidance.

What if I want behavioral support plus medication?

Found includes coaching alongside GLP-1. PlexusDx compounded GLP-1 options allow flexible pairing with behavioral support programs or independent coaching. Discuss combined approaches with your provider to align treatment intensity with personal goals.

How much do PlexusDx compounded GLP-1 options cost?

Compounded semaglutide costs $149/mo; oral semaglutide from $249/mo. Compounded tirzepatide ranges $249/mo injection or $279/mo oral. Costs depend on dose and formulation. Add the Precision Peptide Genetic Test for $99 (with medication) or $298 standalone.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves